Thomas Moser Email & Phone Number

Vienna, At

bit.bio discovery combines single cell functional genomics with best-in-class cellular models to decipher complex cellular pathways and gain a better understanding of disease development. This next-generation CRISPR screening platform will help to understand the role of gene networks at unprecedented scale and resolution to discover and validate novel drug targets and generate deep knowledge on factors that drive the differentiation of stem cells into mature tissue.

Vienna, At

Myllia Biotechnology (former Aelian Biotechnology) combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs.

Cambridge, Cambridgeshire, Gb

Horizon Genomics provides the largest collection of validated human knock-out cell lines thereby empowering biomedical research. It employs a powerful functional genomics platform based on haploid genetics in human cell lines. Horizon Genomics is constructing next generation haploid genetics tools for internal target discovery programs and as part of its commitment to support experimental human genetics in the wider scientific community. In addition, Horizon Genomics offers partnerships to perform haploid genetic screens for drug target discovery and to elucidate drug mechanism of action.

Haplogen Genomics offers human cell lines in which individual genes are knocked out. Our products are based on the haploid human cell lines KBM-7 and HAP1. We provide you with the cell line tools to drive your discoveries.www.haplogen-genomics.com

PONTIS Capital is one of the leading independent growth capital investment firms in Austria. The investment strategy focuses on strong growth and technology-oriented younger companies as well as innovative companies in the lower mid-market. The emphasis is put primarily on the following industries: information-/communication technologies, life sciences and environmental technologies.The investment team of PONTIS possesses venture capital and private equity experience for more than one decade as well as many years of experience in the M&A business and tech-related industries. Portfolio management activities are clearly based on a straight value-creation approach.